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Abstract
Background: Recent advances in the treatment of metastatic unresectable gastric cancers (MGC) include the development
of new antitumor drugs and new regimens for their use. However, the selection of individually designed regimens by gastric
cancer (GC) subtype remains problematic. Here, we investigated the clinical usefulness of programmed chemotherapy.
Methodology/Principal Findings: MGC patients were classified into three groups by clinical condition. We implemented
a chemotherapy program consisting of S-1 combination regimens. Median survival time (MST) of level 1 patients was 416
days (95% CI: 313–506 days), with an overall response rate of 47%. MSTs of level 2 and 3 patients were 208 (95% CI: 153–287
days) and 95 days (95% CI: 28–136 days), respectively. Grade 3–4 toxicities were neutropenia in 12% and anorexia in 6%. All
treatment- related toxicities were resolved, and no treatment-related deaths occurred.
Conclusions/Significance: This program provided reasonable selection of case-matching regimens and may improve the
survival of patients with MGC. Further, it may represent the first clinical tool to provide efficient chemotherapy course
selection for MGC. Ongoing analysis of newly developed drugs and regimens will allow the efficacy of this chemotherapy
program to be improved.
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Introduction
Despite improvements in diagnostic and therapeutic methods,
GC remains a major cause of death worldwide. Since its discovery
by Heidelberger et al in 1957, 5-FU, an antimetabolite with strong
time dependency, has been used in Japan as the gold standard
drug for patients with advanced GC [1]. Because no other regimen
provides better overall survival (OS), 5-FU alone has long been
used as the standard arm in randomized control studies [2].
Recent advances in the treatment of MGC have seen the
introduction of a new anticancer agent, S-1. This drug, a novel
oral fluoropyrimidine developed from a theoretical basis which
combines tegafur (5-FU derivative), gimeracil, and oteracil [3], is
now changing the course of chemotherapy for MGC in Japan
[4,5]. Recent studies have shown synergistic antitumor effects of S-
1 with CDDP [6,7], PTX [8–10], and CPT-11 [11–13]. Based on
evidence from the JCOG9912 and SPIRITS trials [14], S-1 has
now replaced 5-FU, and combination regimens including it are
now widely used in the treatment of GC in Japan [15].
Nevertheless, the selection of case-matching regimens for
individual patients remains problematic. Response to chemother-
apy varies from person to person, and many patients receive
treatment which is suboptimum or even ineffective. The selection
of regimens to manage these difficult cases is hampered by a lack
of suitable guidelines. Here, we conducted a chemotherapy
program that may represent a useful clinical tool in the selection
of chemotherapy courses for MGC.
Methods
Objectives
The results of Japanese phase II studies indicate that sensitivity
to anticancer drugs for GC differs by cellular type and GC
characteristics [16]. For example, CPT-11 is more sensitive to
differentiated than undifferentiated cell-type GC [17], whereas
PTX is conversely more sensitive to undifferentiated than
differentiated GC [18,19]. Based on these findings, and in
consideration of individual clinical conditions, we implemented
a chemotherapy program consisting of S-1 combination regimens
(Figure 1).
Participants and Inclusion Criteria
From April 2004 to June 2007, 77 patients underwent treatment
for MGC at our hospital, of whom 34 were classified as level 1 and
treated with programmed S-1 combination regimens according to
GC subtype (Table 1), 21 were classified as level 2 and treated with
S-1 alone, and 22 were classified as level 3 and treated with best
supportive care (BSC) alone. All patients had histological evidence
of unresectable MGC, cancer stage IV including peritoneal
dissemination, liver metastasis, or distant metastasis. Other
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bone marrow function (neutrophil count $1,500/m l, platelet
count $100,000/m l and hemoglobin $8.0 g/dl); adequate liver
function (serum bilirubin level #2.0 mg/dl and serum trans-
aminase level #2.56ULN (upper limits of normal)); and adequate
renal function (serum creatinine level #1.2 mg/dl).
Evaluations
The primary endpoint was the response rate and the secondary
endpoint was based on the toxicity and OS. The clinical response
was assessed according to the Response Evaluation Criteria in
Solid Tumors (RECIST) [20]. In the CR case, disappearance of all
endoscopic and radiographic evidence of tumor was confirmed for
a minimum of 4 weeks. The therapeutic toxicity was evaluated
according to the National Cancer Institute Common Toxicity
Criteria version 2.0 [21]. The survival time was evaluated at Jan
16, 2010 and was analyzed by Kaplan-Meier method.
Description of Procedures or Investigations undertaken
First, we classified patients into three groups on the basis of
clinical condition. Patients aged less than 80 years with a perfor-
mance status (PS) 0–1 were classified as level 1; these level
1 patients were then further classified into three subgroups
according to the pathologic features of GC. Patients aged 80 years
and older or with PS 2 were classified as level 2 and treated with S-
1 alone; and those with severe complications or with PS 3 or 4
were classified as level 3 and treated with BSC alone. Using this
program, we were easily able to select suitable first- and second-
line regimens for patients with MGC. In each 28-day cycle,
patients received S-1 (80 mg/sq m/day, day 1–14), CDDP
(70 mg/sq m, day 8), PTX (100 mg/sq m, day 1), and CPT-11
(100 mg/sq m, day 1, 15; day 15 was skipped with grade 2
toxicity); or, in the case of CDDP plus PTX plus S-1, they received
S-1 (80 mg/sq m/day, day 1–14), PTX (120 mg/sq m, day 1) and
CDDP (60 mg/sq m, day 14). One chemo-treatment strategy for
MGC is to set strictly scheduled chemotherapy as second-line
treatment, with no pause during the transition from first-line
treatment. Accordingly, we continued administering S-1 as long as
the condition of the patient was not evaluated as level 3, on the
basis that S-1 is an antimetabolite with strong time dependency
which preserves patient quality of life (QOL) even in the case of
a progressive disease (PD).
Figure 1. Programmed chemotherapy for patients with MGC.
doi:10.1371/journal.pone.0038652.g001
Table 1. Results of programmed chemotherapy for patients
with MGC.
patients Treatment PR/CR MST
level 1 (n=34) 1
st line 2
nd line
deifferentiated type
(n=10)
S-1+CDDP S-1+CPT11 5/1 460days
undifferentiated type
(n=18)
S-1+PTX(+CDDP) (S-1+PTX) 7/0 395days
mixed type (n=6) S-1+CDDP S-1+PTX 2/1 481days
S-1+PTX S-1+CDDP
Total S-1 combinations 14/2 416days
level 2 (n=21) S-1 alone 2/1 208days
level 3 (n=22) Best supportive care – 95days
PR=partial response, CR=complete response, MST=median survival time.
doi:10.1371/journal.pone.0038652.t001
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Dose adjustments were made if grade 3–4 toxicity was seen. If
grade 3–4 toxicity was present during a 4-week cycle, the
administration of every anticancer drug was stopped in that cycle.
In the next cycle when toxicity resolved, CDDP, PTX or CPT-11
was reduced by 20%, while S-1 was not reduced. The dose of S-1
was reduced by 30% when renal toxicity was seen (serum
creatinine level $1.2).
Ethics
The study was carried out in accordance with the Declaration of
Helsinki. The ethics committee of cancer board, Toyota Memorial
Hospital approved all of the regimens used in the program.
Written informed consent was obtained from all patients prior to
participation, some after visiting another hospital to receive
a second opinion. The study started before Ottawa statement
and had no compulsory registration of clinic trials.
Results
Response to Treatment
The survival curve of each level is shown in Figure 2. Median
survival time (MST) of level 1 patients was 416 days (95% CI:
313–506 days), with an overall response rate of 47%. MSTs of
level 2 and 3 patients were 208 (95% CI: 153–287 days) and 95
days (95% CI: 28–136 days), respectively. With regard to the
outcome of level 1 patients, all 3 subgroups showed an MST of 13
months or more (Table 1). Further, the relationship between
treatment time and OS correlated well, except in one complete
response (CR) case (Figure 3).
Adverse Events
Grade 3–4 toxicities were neutropenia in 12% and anorexia in
6%. All treatment- related toxicities were resolved, and no
treatment-related deaths occurred.
Representative Cases
Case 1: A 60-year-old male was admitted with melena and
diagnosed with differentiated-type MGC with liver metastasis and
local lymph node metastasis. He was classified as level 1 and
treated with S-1 plus CDDP combination for four cycles. CR was
confirmed radiologically (Figure 4) and endoscopically. Two years
later, he was informed of local lymphadenopathy but declined
surgery. CR was reacquired after an additional two cycles of S-1
plus CDDP. In this case, strictly scheduled chemotherapy
provided a maximum anti-tumor effect.
Case 2: A 70-year-old male diagnosed with differentiated-type
MGC with massive liver metastasis was treated with S-1 plus
CDDP combination for two cycles. Following radiological
confirmation of PD, he was treated with four cycles of S-1 plus
CPT-11, on the basis that even when one S-1 combination therapy
is evaluated as PD, another might be effective. We therefore
selected the next S-1 combination in accordance with the program
for this patient, and he finally achieved partial response (PR)
(Figure 5).
Case 3: A 82 year old female presented with anorexia and
anemia. She had undifferentiated-type MGC and her condition
was classified as level 2. She was given a blood transfusion and
treatment was started with S-1 alone on November 5, 2004. She
died from liver metastasis, while pathological CR was found by
stomach dissection. Because she refused further chemotherapy, we
stopped giving S-1 on May 9, 2005. Her tumor markers increased
markedly after we stopped S-1 treatment, suggesting that S-1
should have been effective for controlling this case (Figure 6). We
propose that S-1 should be given continuously, unless it is toxic.
Discussion
The aim of this study was to evaluate the usefulness of
programmed chemotherapy for patients with MGC. Results
showed the value of this strategy for the selection of case-matching
regimens for patients with MGC. Additional data will confirm this
program, and provide for its ongoing refinement.
While a substantial portion of the more than 50,000 deaths
annually from GC in Japan are due to MGC, response to
chemotherapy in these patients varies widely, and some in fact
receive ineffective treatment. Against this background, recent
studies have shown synergistic antitumor effects of S-1, a new
anticancer agent which has changed the course of chemotherapy
Figure 2. Survival curve of Level 1, Level 2 and Level 3: OS=Overall Survival.
doi:10.1371/journal.pone.0038652.g002
Programmed Chemotherapy for Gastric Cancer
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38652for MGC in Japan, and CDDP, CPT-11, and taxenes [6–15].
Novel approaches to patient selection and the individual design of
chemotherapy regimens are thus urgently required, but treatment
course programs for patients with MGC have not been reported.
We therefore conducted a prudent initial investigation of
chemotherapy programs composed of fixed S-1 combination
regimens.
Evidence from the JCOG 9912 and SPIRITS trials [14] has
established the S-1 plus CDDP combination as the standard first-
line regime for MGC in Japan. The consensus for this
combination is based on evidence from the SPIRITS trial, which
confirmed OS prolongation as the primary endpoint. However,
these trials also allowed second- or third-line treatments on ethical
grounds. OS is actually an outcome of the aggregate of all
therapies, including first-, second-, and third-line treatment with
sequential BSC. In some studies, completely ineffectual first-line
therapy might be deemed as markedly effective even when it is in
fact second- or third-line therapy which rescues the patient. For
example, our case 2 patient might have died prematurely from
liver failure with the standard first-line treatment of S-1 plus
CDDP, but actually survived for 496 days with the second-line
treatment of S-1 plus CPT-11. We evaluated this case as PD with
S-1 plus CDDP, and PR with subsequent S-1 plus CPT-11.
Because sensitivity to anticancer drugs appears to differ by cellular
type and GC characteristics, outcomes will be optimized by the
selection of an individually designed regimen or change to
a suitable second-line regimen.
In Japan, the new anticancer agent S-1 has replaced 5-FU for
MGC and is now considered a key drug in this use, with many
combination regimens which incorporate it now in use [8,11,15].
Many clinical trials of combination chemotherapy with S-1,
CDDP, CPT-11, and PTX have obtained response rates higher
than 30%. With regard to effectiveness, CDDP or CPT-11 is
reported to be effective for differentiated-type GC [16,17], and
Figure 3. Correlation between treatment time and OS. A good correlation was seen between treatment time and survival time.
doi:10.1371/journal.pone.0038652.g003
Figure 4. CT of Case 1, before (left; 02/08/’05) and after (right; 19/02/’09) the programmed chemotherapy. 60 yrs old male with melena
was introduced to our hospital. He had differentiated-type MGC with liver metastasis and local lymph metastases. He was classified as level 1 and was
treated with S-1 plus CDDP combination for 6 cools. CR was confirmed radiologically.
doi:10.1371/journal.pone.0038652.g004
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Japanese phase II study results, we conducted a chemotherapy
program and investigated the effectiveness of this program.
Prognosis should be improved by the timely selection and ongoing
evaluation of individually matched regimens for patients with
various GC subtypes. A second important point is the construction
of effective second- and third-line regimens which extend re-
mission and survival. We selected S-1-based regimens in our
program on the basis of their time-dependent anti-tumor effects
with lower toxicity and the convenience of oral delivery. Recently,
S-1-based sequential chemotherapy as second-line treatment was
reported to prolong OS with less toxicity than other second-line
regimens which did not include S-1 [22].
In the present study, MSTs for levels 2 and 3 were 208 days
(95% CI: 153–287 days) and 95 days (95% CI: 28–136 days),
respectively, while that of level 1 was 416 days (95% CI: 313–506
days), giving an overall response rate of 47%. These results
indicate the clinical value of this program as a tool for the selection
of case-matching regimens for patients with MGC. In addition,
a significant correlation was seen between treatment time and
survival. Our strategy of giving S-1 even to PD patients with PS
0 to 2 appears effective, and we recommend that administration be
given continuously to preserve QOL, provided toxicity is accept-
able.
Our program provides the efficient sequential use of anticancer
drugs for patients with MGC. We consider that this program may
provide superior selection of case-matching treatment to those
previously reported and may further improve the survival of
patients with MGC. Ongoing analysis of newly developed drugs
and regimens will allow further refinement of the program.
Figure 5. Endoscopic features of Case 2. PR was confirmed in Case 2 by endoscopic features before (left; 21/02/’07) and after (right; 29/06/’07)
programmed chemotherapy.
doi:10.1371/journal.pone.0038652.g005
Figure 6. The course of tumor markers in Case 3. CEA and CA19-9 increased markedly when we stopped giving S-1, suggesting that S-1 was
still effective to control the case.
doi:10.1371/journal.pone.0038652.g006
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matching regimens for patients with MGC. Additional data will
allow the efficacy of the program to be confirmed, and provide for
ongoing refinement. Further clinical trials should investigate the
sequential use of anticancer drugs, molecular target drugs, and
surgery, as well as combinations thereof.
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